J and J Agrees to Acquire Ollin Biosciences

Company Johnson & Johnson; Ollin Biosciences; Blackstone Event Type Acquisition ($2.2 billion upfront) with Blackstone development funding Modality Bispecific minibody Asset OLN324 Target VEGF; Ang2 Disease Area Wet AMD; diabetic macular edema Summary Johnson & Johnson agreed to buy Ollin for $2.2 billion upfront plus…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *